Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Patented inhibitors of p53–Mdm2 interaction (2006 – 2008)

25 Jan 2010

Abstract excerpt

IMPORTANCE OF THE FIELD: Induction of apoptosis by reactivation of p53 in cancer cells is an emerging therapeutic concept for the treatment of cancer. The discovery and design of novel small molecules that block the p53-Mdm2 protein interaction, thereby activating p53, has provided interesting drug candidates that have currently entered clinical trials or are at the preclinical development stage. AREAS COVERED IN...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to Cancer-related Molecular Pathways
Share to Cell death mechanisms and regulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 20100001
DOI: 10.1517/13543770903514129

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Patented inhibitors of p53–Mdm2 interaction (2006 – 2008)PMID 20100001Read ↗

p53–Mdm2 inhibitors: patent review (2009 – 2010)Semantic proximity Read ↗

Mdm2 and MdmX inhibitors for the treatment of cancer: a patent review (2011 – present)Semantic proximity Read ↗

MDM2-p53 Interaction Inhibitors: The Current State-of-Art and Updated Patent Review (2010-Present)Semantic proximity Read ↗

Targeting p53-MDM2 Interaction Using Small Molecule Inhibitors and the Challenges Needed to be AddressedSemantic proximity Read ↗

Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trialsSemantic proximity Read ↗

Therapeutics Targeting p53-MDM2 Interaction to Induce Cancer Cell DeathSemantic proximity Read ↗

Small Molecule Inhibitors of the p53-MDM2Semantic proximity Read ↗

Targeting the MDM2-p53 Interaction for Cancer TherapySemantic proximity Read ↗

Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?Semantic proximity Read ↗

Discovery of Potent and Selective p53-MDM2 Protein–Protein Interaction Inhibitors as Anticancer DrugsSemantic proximity Read ↗

A therapeutic patent overview of MDM2/X-targeted therapies (2014–2018)Semantic proximity Read ↗

Chemical Variations on the p53 Reactivation ThemeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.